GCAR and Purdue Pharma L.P. Announce Initiation of Tinostamustine in GBM AGILE Trial

Trial StartTinostamustinePositive

AI Analysis

Summary

Purdue Pharma and GCAR announced the initiation of Tinostamustine enrollment in the GBM AGILE registrational-intent Phase 2/3 adaptive platform trial for glioblastoma patients.

Clinical Trial Data

Phase

Phase 2/3

Outcome Details

Tinostamustine initiation in GBM AGILE registrational-intent Phase 2/3 adaptive platform trial

Importance:5/10

Sentiment:

0.30

glioblastomaadaptive trialtinostamustineregistrational-intentGBM AGILE

Related Companies

$ADPT $GMRE-PA

Read the original article

Published by PR Newswire Biotech on April 8, 2026 2:00 PM

Read Original